TH細胞における標的型TGF-βシグナルブロックによるがん免疫療法
Shun Li1, Ming Liu1, Mytrang H Do1,2
1Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature
|October 22, 2020
まとめ
CD4+ T細胞に変換成長因子β (TGF-β) を標的にすることで,腫瘍の微小環境を改造し,がんに対する免疫力を高めます. このアプローチは腫瘍の成長を抑制し 癌治療の新たな戦略を提供します
科学分野:
- 免疫学
- 腫瘍学
- 癌 生物学
背景:
- 腫瘍細胞や血管内皮成長因子A (VEGFA) を標的としたがん治療は,しばしば抵抗に直面する.
- 変形成長因子β (TGF-β) は,Tヘルパー2 (TH2) 細胞媒介によるがんに対する免疫を抑制することが知られている.
- 既存の治療には限界があり,腫瘍の微小環境を標的とした新しい治療戦略が必要である.
研究 の 目的:
- 特にCD4+T細胞内のTGF-βシグナル伝達を阻害する治療の可能性を調査する.
- Tヘルパー細胞における標的型TGF-β阻害のための新しい二特異性分子を開発し評価する.
- 腫瘍の進行と腫瘍の微小環境に対する 標的の封鎖の影響を評価する.
主な方法:
- 従来の治療法に抵抗する 乳がんのマウスモデルを使用しました
- TGF-β受容体II (TGFBR2) と抗CD4抗体を組み合わせた,双固有の分子であるCD4 TGF-βトラップ (4T-トラップ) を設計した.
- TH細胞のTGF-βシグナル伝達,腫瘍血管,癌細胞死に対する効果を評価するために4T- トラップを投与した.
主要な成果:
- CD4+ T細胞におけるTGFBR2の誘導性消去は,耐性乳がんモデルにおける腫瘍の成長を抑制した.
- 4T- トラップは,腫瘍排水リンパ節におけるTH細胞のTGF- βシグナル伝達を選択的に抑制した.
- この抑制により,腫瘍血管の再組織化,インタールイキン-4 (IL-4) に依存した癌細胞死,および腫瘍低酸素症が発生した.
- 4T- トラップとVEGF抑制を併用すると,がん細胞死と抗腫瘍効果が強化される.
結論:
- CD4+T細胞におけるTGF-βシグナル伝達をターゲットにブロックすることは,腫瘍の微小環境を再構成する有効な戦略です.
- このアプローチは,抗腫瘍免疫を強化することで,がんの進行を効果的に抑制します.
- 設計された4Tトラップ分子は 腫瘍環境に焦点を当てた新しいがん治療の開発の可能性を示しています
関連する概念動画
01:27Tumor Immunotherapy
1.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.2K
02:57Targeted Cancer Therapies
8.3K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.3K
02:50Combination Therapies and Personalized Medicine
5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
01:30Cancer Vaccines
801
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
801
02:38Mitogens and the Cell Cycle
7.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
01:16TGF - β Signaling Pathway
9.8K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
9.8K